Vivacelle Bio
Vivacelle Bio is a late-stage biopharma company focused on developing life-saving treatments for shock and trauma, utilizing patented phospholipid nanoparticle technology. Their pipeline includes VBI-S, a Phase 3-ready asset for septic shock, and VBI-1, a candidate for hemorrhagic shock, with ongoing clinical trials and a strong patent portfolio. The company aims to address unmet medical needs in critical illnesses caused by shock and trauma, with support from government agencies and venture capital.
Industries
Nr. of Employees
small (1-50)
Patents
Compositions and methods for treating or preventing multiple organ dysfunction syndrome
US-12036321-B2
View DetailsMethods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US-9622968-B2
View DetailsMethods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US-9439855-B2
View DetailsMethods and compositions for treating conditions related to lack of blood supply, shock, and neuronal injuries
US-9387162-B2
View DetailsMethods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US-8906855-B2
View Details
Compositions and methods for treating or preventing multiple organ dysfunction syndrome
US-12036321-B2
View DetailsMethods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US-9622968-B2
View DetailsMethods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US-9439855-B2
View DetailsMethods and compositions for treating conditions related to lack of blood supply, shock, and neuronal injuries
US-9387162-B2
View DetailsMethods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US-8906855-B2
View DetailsProducts
Phase 3-ready phospholipid nanoparticle intravenous cardiovascular support fluid (lead clinical asset)
An intravenously administered, volume-expanding colloid composed of phospholipid nanoparticles formulated to absorb and redistribute nitric oxide/nitrite to reverse hypotension and improve organ perfusion in patients with septic-shock-associated hypovolemia.
Phase 2-ready refined phospholipid nanoparticle perfusion fluid for hemorrhagic shock
A refined version of the phospholipid nanoparticle fluid formulated for treatment of hemorrhagic shock and mitigation of reperfusion injury, developed for progression into mid-stage clinical evaluation.
Phase 3-ready phospholipid nanoparticle intravenous cardiovascular support fluid (lead clinical asset)
An intravenously administered, volume-expanding colloid composed of phospholipid nanoparticles formulated to absorb and redistribute nitric oxide/nitrite to reverse hypotension and improve organ perfusion in patients with septic-shock-associated hypovolemia.
Phase 2-ready refined phospholipid nanoparticle perfusion fluid for hemorrhagic shock
A refined version of the phospholipid nanoparticle fluid formulated for treatment of hemorrhagic shock and mitigation of reperfusion injury, developed for progression into mid-stage clinical evaluation.
Services
Negotiation and collaboration for out-licensing, co-development, global strategic development, and commercialization of nanoparticle-based critical care therapeutics.
Negotiation and collaboration for out-licensing, co-development, global strategic development, and commercialization of nanoparticle-based critical care therapeutics.
Expertise Areas
- Clinical trial management in critical care (Phase II–III)
- Nanoparticle formulation and colloid engineering
- Shock and trauma therapeutics development
- Mechanism-of-action and translational research
Key Technologies
- Phospholipid nanoparticle formulations
- Micellar colloids / lipid bilayer and micelle systems
- Intravenous volume-expanding colloidal fluids
- Nitric oxide / nitrite absorption and redistribution mechanism
News & Updates
Vivacelle Bio announced its participation in BIO Partnering @ JPM Week 2025 in San Francisco, where management will conduct meetings with investors and partners to showcase their clinical development strategy and milestones.
A landmark study published in The Lancet's eClinicalMedicine shows VBI-S's potential in treating refractory hypotension in septic shock patients, achieving 100% primary endpoint success and significant improvements in organ function.
Vivacelle Bio announced enrollment of the first patient in a Phase 3 trial for VBI-S to treat hypovolemia due to septic shock, addressing both absolute and relative hypovolemia caused by overproduction of nitric oxide.
Vivacelle Bio announced the integration of its Sub-Saharan Africa strategy into its Series B financing round, aiming to expand access and development in the region.
Cuthbert Simpkins MD, President and Chief Innovation Officer, will present data on Vivacelle's clinical programs at the 2024 BIO International Convention, emphasizing the progress of VBI-S and pipeline development.
Vivacelle Bio announced its participation in BIO Partnering @ JPM Week 2025 in San Francisco, where management will conduct meetings with investors and partners to showcase their clinical development strategy and milestones.
A landmark study published in The Lancet's eClinicalMedicine shows VBI-S's potential in treating refractory hypotension in septic shock patients, achieving 100% primary endpoint success and significant improvements in organ function.
Vivacelle Bio announced enrollment of the first patient in a Phase 3 trial for VBI-S to treat hypovolemia due to septic shock, addressing both absolute and relative hypovolemia caused by overproduction of nitric oxide.
Vivacelle Bio announced the integration of its Sub-Saharan Africa strategy into its Series B financing round, aiming to expand access and development in the region.
Cuthbert Simpkins MD, President and Chief Innovation Officer, will present data on Vivacelle's clinical programs at the 2024 BIO International Convention, emphasizing the progress of VBI-S and pipeline development.